POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (ET-MF)

Clinical trials for POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (ET-MF) explained in plain language.

Never miss a new study

Get alerted when new POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (ET-MF) trials appear

Sign up with your email to follow new studies for POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (ET-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug trial offers hope for Tough-to-Treat blood cancer patients

Disease control Recruiting now

This study is testing whether an oral medication called reparixin can help control advanced myelofibrosis, a serious bone marrow cancer. It's for patients whose disease has worsened despite standard treatments or who cannot take those treatments. Researchers will measure if the d…

Matched conditions: POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (ET-MF)

Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (ET-MF)

Get alerted when new POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (ET-MF) trials appear

New drug trial offers hope for Tough-to-Treat blood cancer patients